RCS - Angle PLC - Parsortix HER2 assay showcased at AACR 2024

AngleAnnouncement

08/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5614Ja&default-theme=true

RNS Number : 5614J  Angle PLC  08 April 2024

 For immediate release  8 April 2024

 

ANGLE plc ("the Company")

 

PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE

 

CTC HER2 assay being developed for HER2 targeted drugs and antibody drug
conjugates presented at internationally renowned AACR Annual Meeting 2024

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce its participation at
the American Association for Cancer Research (AACR) Annual Meeting, San Diego,
US between 5 to 10 April 2024.

 

ANGLE is presenting a poster entitled the "Development and analytical
validation of a novel assay for HER2 assessment on circulating tumor cells
harvested using the Parsortix(®) system and incorporating BioView imaging
technologies". The poster pertains to the Company's collaboration with
BioView, for which ANGLE is developing an end-to-end assay for the evaluation
of human epidermal growth factor receptor 2 (HER2) gene amplification and
protein expression in circulating tumour cells (CTCs) harvested using the
Parsortix system from the blood of metastatic breast cancer (MBC) patients.
The presented data showcases the development and analytical validation of this
assay using the BioView Allegro Plus, an automated, high-throughput platform
for imaging and identification of CTCs. The system facilitates the assessment
of CTC classification, HER2 biomarker expression, and assessment of HER2 gene
copy number by Fluorescence In Situ Hybridization.

 

ANGLE's in-house study reports the successful identification of the HER2
protein and gene copy information from cell targets with minimal cell loss.
 The analysis of clinical samples using the assay has demonstrated the
ability to detect HER2 positive CTCs in patients who were previously HER2
negative based on a primary tissue biopsy. This assay is being developed as a
product kit for minimally invasive identification of HER2 positive and HER2
low patients, who may benefit from HER2-targeted therapies and HER2
antibody-drug conjugates. The ability to monitor HER2 status over time from
repeat blood samples may provide valuable data for assessing treatment
options. The combination of ANGLE's Parsortix system for harvesting CTCs for
analysis, BioView's imaging and analysis technologies, and the new HER2 CTC
staining kit under development is intended to provide an easy to use assay
based on a simple blood test, providing an up-to-date HER2 status for breast
cancer patients on a repeat basis.

 

The evaluation of HER2 status via tissue biopsy is the current standard of
care for guiding breast cancer patient treatment plans. However, tissue biopsy
is invasive and difficult to repeat throughout the patient care pathway.
Moreover, discordance between a primary tumour sample and a metastatic site is
common. Liquid biopsy evaluation of HER2 status is a minimally invasive
technique, suitable for repeat monitoring and capturing changes in disease
status during and after treatment. Specifically, CTCs, as a liquid biopsy
analyte have shown considerable potential to provide key information on HER2
status in breast cancer patients. One third-party study of 575 breast cancer
patients found that HER2 status had changed in 38% of patients from the
original primary tissue biopsy to the metastatic tissue biopsy, at disease
recurrence(1).

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are delighted to be presenting results from our HER2 assay development
programme at the AACR's Annual Meeting as one of the key annual events in the
cancer research calendar. We are excited to engage with the multidisciplinary
community of attendees at this preeminent event to showcase this novel HER2
assay in partnership with BioView."

 

BioView Chief Scientific Officer, Chassidy Johnson commented:

"We are pleased to present both analytical and clinical data to support this
novel HER2 assay being developed in collaboration with ANGLE. We believe this
HER2 CTC assay has potential to greatly impact metastatic breast cancer
patient care and look forward to this presentation at the 2024 AACR Annual
Meeting."

 

About the AACR:

The AACR is the first and largest cancer research organisation dedicated to
the prevention and cure of cancer. The AACR Annual Meeting is described as the
focal point of the cancer research community, where cutting edge innovations
in cancer science and medicine are presented from internationally renowned
researchers and institutions. The annual conference is attended by scientists,
clinicians, healthcare professionals, patient advocates and industry
representatives, with last year's conference attracting over 21,000 attendees.

 

1.  Miglietta F et al. Evolution of HER2-low expression from primary to
recurrent breast cancer. NPJ Breast Cancer. 2021 Oct 12;7(1):137

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK. Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKPBKPBKDOQK